Zydus focuses on the first 30 molecules; Md Sharvil Patel expects double-digit growth for India

Zydus Lifesciences is focused on the top 30 molecules, chief executive Sharvil Patel said on Wednesday, adding that the company expects double-digit growth for India.

In an interview with CNBC-TV18, he said, “At the stage where we are currently focused on the top 30 molecules with new introductions on the proprietary molecule side, we are poised to deliver above market growth. and double-single-digit growth for the formulations business in India and we are confident to achieve this.

Speaking of US business, he said it has always been a cyclical business and should be viewed in a 3-5 year window. “We believe that any good company with a strong portfolio, good cost, good position, good upstream integration can continue to do well in the US generics markets,” Patel said.

He further said that the company expects generic launches in the next 18 months to help US companies and is expected to increase revenue up to $1 billion from these launches.

For more details, watch the attached video

First post: STI


Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.
Back to top button